A new injectable GLP-1 called zovaglutide is going into a Phase 2 trial in October, and the question it is built to answer is one a lot of people on semaglutide have wondered about privately: what happens if you move from the drug you are on to a different one in the same family.
The study is run by Beijing QL Biopharmaceutical and will enroll 210 adults with obesity. Everyone starts on semaglutide and titrates up to the 2.4 mg dose. From there the group splits. Some participants switch over to zovaglutide, in two different arms, and the rest stay on semaglutide as the comparison.
What it is measuring is safety and tolerability, which in plain terms means side effects and whether people can stay on the drug without feeling terrible. It is not measuring which one takes more weight off. That is normal for this stage: a Phase 2 study is asking whether a drug is workable before anyone spends years asking whether it is better.
The timeline is long. Enrollment has not opened yet, the study is scheduled to begin on October 12, 2026, and it is not expected to finish until March 2028. A Phase 3 program would come after that, and approval after that, so zovaglutide is not a medicine anyone will be filling a prescription for soon.
It is still worth knowing about for one reason. Switching between GLP-1s is something people already do, usually because of supply, cost or side effects, and usually without much published evidence to go on. A trial designed around the switch itself is the kind of study that eventually gives a prescriber something better than a guess.
Nothing here changes what is available to you this month. What it does is put a question people have been answering by trial and error into an actual trial, which is how it stops being guesswork a couple of years from now.
Key details
Zovaglutide is an experimental injectable GLP-1 from Beijing QL Biopharmaceutical, a Chinese drugmaker.
The Phase 2 study, NCT07812597, will enroll 210 adults with obesity and is not yet recruiting.
Participants titrate up to semaglutide 2.4 mg, then some switch to zovaglutide in two arms while the rest stay on semaglutide.
The trial measures safety and tolerability, meaning side effects and how well people tolerate the drug, not weight loss.
It is scheduled to start October 12, 2026 and finish in March 2028, so there is no direct effect on access now.
Sources
ClinicalTrials.gov: A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
Originally published on GLP-1 Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.